Cargando…

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma

BACKGROUND: The goal of this study was to retrospectively analyze the efficacy and safety of pembrolizumab in the real-world treatment of soft tissue sarcoma (STS). METHODS: We analyzed 38 patients who suffered from STS and received pembrolizumab treatment from July 2017 to December 2018 in our hosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jiayong, Fan, Zhengfu, Bai, Chujie, Li, Shu, Xue, Ruifeng, Gao, Tian, Zhang, Lu, Tan, Zhichao, Fang, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944271/ https://www.ncbi.nlm.nih.gov/pubmed/33708966 http://dx.doi.org/10.21037/atm-21-49

Ejemplares similares

Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases
por: Liu, Jiayong, et al.
Publicado: (2020)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study
por: Tan, Zhichao, et al.
Publicado: (2022)

Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study
por: Tan, Zhichao, et al.
Publicado: (2022)

KIF18B promotes tumor progression in osteosarcoma by activating β-catenin
por: Gao, Tian, et al.
Publicado: (2020)

The efficacy of (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients
por: Liu, Jiayong, et al.
Publicado: (2022)

Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma
por: Bai, Chujie, et al.
Publicado: (2015)

AZGP1 inhibits soft tissue sarcoma cells invasion and migration
por: Liu, Jiayong, et al.
Publicado: (2018)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019)

Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence
por: Spałek, Mateusz Jacek, et al.
Publicado: (2022)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Chemotherapeutic drugs for soft tissue sarcomas: a review
por: Tian, Zhichao, et al.
Publicado: (2023)

PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
por: Scheinberg, Tahlia, et al.
Publicado: (2020)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Nanomaterial Technology and Soft Tissue Sarcomas
por: Zhou, Changkai, et al.
Publicado: (2022)

Management of Advanced Adult Soft Tissue Sarcoma
por: Bramwell, Vivien H. C.
Publicado: (2003)

Systemic Therapy for Advanced Soft Tissue Sarcomas
por: Riedel, Richard F
Publicado: (2012)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
por: Tian, Zhichao, et al.
Publicado: (2020)

Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan
por: Nakamura, Tomoki, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
por: Zhang, Ren‐Shu, et al.
Publicado: (2022)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
por: Strassmann, Dennis, et al.
Publicado: (2021)

Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study
por: Liu, Zengjun, et al.
Publicado: (2023)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Superficial Soft-Tissue Sarcomas Rarely Require Advanced Soft-Tissue Reconstruction following Resection
por: Eward, William C., et al.
Publicado: (2017)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Advances in soft-tissue sarcoma – There are no mistakes, only lessons to learn!
por: Rastogi, Sameer, et al.
Publicado: (2019)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p4o388795qm7hcsprlmubno87r